Welcome to our dedicated page for CollPlant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on CollPlant Biotechnologies stock.
CollPlant Biotechnologies Ltd. develops regenerative and aesthetic medicine technologies based on plant-derived recombinant human collagen, or rhCollagen. News about CLGN centers on its BioInk and 3D bioprinting portfolio, including Collink.3D and BioFlex, as well as medical aesthetics programs such as photocurable dermal filler technology and tissue-regeneration applications.
Company updates also cover operating and financial results, distribution expansion for rhCollagen and BioInk products, Vergenix STR commercialization, intellectual-property activity, collaboration developments, capital actions and Nasdaq listing-compliance matters.
CollPlant (Nasdaq: CLGN) launched a redesigned corporate website on March 18, 2026 to centralize investor, partner, and stakeholder information. The site expands details on the company's rhCollagen technology, product pipeline (breast implants, dermal fillers, bioinks), collaborations, SEC filings, and governance.
The update aims to improve transparency, accessibility, and engagement as CollPlant advances its clinical and preclinical programs and commercialization objectives.
CollPlant Biotechnologies (Nasdaq: CLGN) said it will report full-year 2025 financial results on Thursday, March 26, 2026, before the opening of U.S. financial markets. The announcement sets a date for earnings disclosure and signals when investors can expect results and related company materials.
CollPlant (Nasdaq: CLGN) announced the Korean Patent Office allowed a patent for its photocurable dermal filler covering a polymerizable rhCollagen solution for in situ light-activated tissue augmentation.
The allowance extends protection through 2039, follows a recent Japanese grant, and adds to granted patents in the US, Europe, China, Brazil, Australia, and Israel. According to the company, the global injectable soft-tissue filler market exceeds $6 billion. CollPlant noted a 2021 development and global commercialization agreement with Allergan (AbbVie).
CollPlant (NASDAQ: CLGN) launched BioFlex, a ready-to-print rhCollagen kit for DLP 3D bioprinting, aimed at drug discovery, engineered tissues and organ fabrication.
BioFlex bundles Collink.3D 50 biodegradable polymer with proprietary photoactive agents and formulation guidelines to enable tunable, high-resolution, reproducible bioinks and faster development.
CollPlant (NASDAQ: CLGN) announced Feb 17, 2026 strategic positioning of a photocurable rhCollagen dermal filler to address facial volume loss linked to rapid weight loss, including patients on GLP-1 therapies. The platform is preclinical and aims to restore structure, integrate with tissue, and potentially improve skin quality over time.
The company is evaluating clinical and commercial pathways to address a growing aesthetic need driven by expanding GLP-1 use.
CollPlant (NASDAQ: CLGN) entered a definitive agreement for a registered direct offering of 1,600,000 ordinary shares at $1.25 per share for gross proceeds of approximately $2.0 million. Concurrently, unregistered Series A and B warrants to purchase up to 1,600,000 shares each will be issued.
The Series A warrants have a $1.25 exercise price and expire five years after the effective registration date; Series B warrants have a $1.25 exercise price and expire 18 months after that date. The offering is expected to close on or about February 6, 2026, with H.C. Wainwright as placement agent.
CollPlant Biotechnologies (Nasdaq: CLGN) reported third-quarter 2025 results and a corporate update on Nov 26, 2025. Key commercial moves include a new U.S. logistics center becoming operational this quarter and appointment of a North America commercial head to expand rhCollagen and BioInk distribution.
Financial highlights: Q3 GAAP revenue $77k (vs $4k year-ago); 9M revenue $2.3M driven by a $2.0M AbbVie milestone; cash $8.5M as of Sept 30, 2025; GAAP 9M net loss narrowed to $8.3M from $12.7M. Company initiated a ~25% workforce reduction and cost-prioritization to extend runway.
CollPlant Biotechnologies (Nasdaq: CLGN) announced it will report third quarter 2025 financial results on Wednesday, November 26, 2025, before the U.S. market open. The company develops non-animal-derived rhCollagen products for tissue regeneration and medical aesthetics. Investors can expect the company to release results and any accompanying commentary or materials on that date.
CollPlant (Nasdaq: CLGN) announced an expansion of its North American distribution through a new U.S.-based logistics center, scheduled to become operational this quarter (announcement dated Oct 27, 2025).
The hub will provide full cGMP-compliant storage and distribution, serve as a clinical supply depot, and support rhCollagen and BioInk product lines in the U.S. and Canada. Facility features include cGMP-controlled environments, cloud-based temperature monitoring, advanced emergency backup, AI-powered security, and remote inventory management.
Management said local inventory and improved logistics are expected to increase efficiency, reduce shipping time, and strengthen support for customers and clinical partners in North America.
CollPlant (Nasdaq: CLGN) announced that a head-to-head study by Technion's Levenberg Lab found its rhCollagen-based bioink Collink.3D™ outperformed Matrigel® on key lab metrics. Collink.3D™ reportedly showed enhanced mechanical strength, elasticity, and stability, supporting organized and long-lasting tissue formation in a reproducible, animal-free format.
The release highlights potential application in tissue engineering, regenerative medicine, and drug discovery and notes the global basement membrane matrix market was ~$96M in 2024, projected to reach $201M by 2031 (CAGR 11.2%).